论文部分内容阅读
目的评价培哚普利对慢性心力衰竭(CHF)患者血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制物-1(PAI-1)水平的影响。方法采用酶联免疫吸附法测定60例CHF患者(CHF组)及20例健康人(正常对照组)血浆t-PA、PAI-1水平。CHF组患者又随机均分为常规治疗亚组和培哚普利亚组。培哚普利亚组在常规治疗基础上加用培哚普利2~4mg,每日1次。所有CHF患者治疗2周后复测血浆t-PA、PAI-1水平。结果CHF患者血浆t-PA、PAI-1水平比正常对照组明显增高(P<0.01)。治疗后,培哚普利亚组血浆PAI-1水平比常规治疗亚组明显降低(P<0.01),血浆t-PA水平比常规治疗亚组明显升高(P<0.01)。结论培哚普利不仅可降低PAI-1水平,而且可升高t-PA水平,改善内源性纤溶功能。
Objective To evaluate the effects of perindopril on the levels of plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in patients with chronic heart failure (CHF). Methods The levels of plasma t-PA and PAI-1 in 60 patients with CHF (CHF group) and 20 healthy people (normal control group) were measured by enzyme-linked immunosorbent assay. CHF patients were randomly divided into routine treatment subgroup and perindopril subgroup. Perindopril group with routine treatment based on the use of perindopril 2 ~ 4mg, 1 day. Plasma levels of t-PA and PAI-1 were measured in all CHF patients after 2 weeks of treatment. Results The plasma levels of t-PA and PAI-1 in CHF patients were significantly higher than those in normal controls (P <0.01). Plasma PAI-1 level in the perindopril group was significantly lower than that in the routine treatment group (P <0.01), and plasma t-PA level was significantly higher than that in the routine treatment subgroup (P <0.01) after treatment. Conclusion Perindopril can not only reduce the level of PAI-1, but also increase the level of t-PA and improve the endogenous fibrinolytic function.